

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTALAB1643

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * Welcome to STN International * * * * * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 JUL 02 LMEDLINE coverage updated
NEWS 3 JUL 02 SCISEARCH enhanced with complete author names
NEWS 4 JUL 02 CHEMCATS accession numbers revised
NEWS 5 JUL 02 CA/CAplus enhanced with utility model patents from China
NEWS 6 JUL 16 CAplus enhanced with French and German abstracts
NEWS 7 JUL 18 CA/CAplus patent coverage enhanced
NEWS 8 JUL 26 USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS 9 JUL 30 USGENE now available on STN
NEWS 10 AUG 06 CAS REGISTRY enhanced with new experimental property tags
NEWS 11 AUG 06 FSTA enhanced with new thesaurus edition
NEWS 12 AUG 13 CA/CAplus enhanced with additional kind codes for granted
 patents
NEWS 13 AUG 20 CA/CAplus enhanced with CAS indexing in pre-1907 records
NEWS 14 AUG 27 Full-text patent databases enhanced with predefined
 patent family display formats from INPADOCDB
NEWS 15 AUG 27 USPATOLD now available on STN
NEWS 16 AUG 28 CAS REGISTRY enhanced with additional experimental
 spectral property data
NEWS 17 SEP 07 STN AnaVist, Version 2.0, now available with Derwent
 World Patents Index
NEWS 18 SEP 13 FORIS renamed to SOFIS
NEWS 19 SEP 13 INPADOCDB enhanced with monthly SDI frequency
NEWS 20 SEP 17 CA/CAplus enhanced with printed CA page images from
 1967-1998
NEWS 21 SEP 17 CAplus coverage extended to include traditional medicine
 patents
NEWS 22 SEP 24 EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 23 OCT 02 CA/CAplus enhanced with pre-1907 records from Chemisches
 Zentralblatt

NEWS 24 OCT 19 BEILSTEIN updated with new compounds
NEWS 25 NOV 15 Derwent Indian patent publication number format enhanced
NEWS 26 NOV 19 WPIX enhanced with XML display format
NEWS 27 NOV 30 ICSD reloaded with enhancements
NEWS 28 DEC 04 LINPADOOCDB now available on STN

NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2.

CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 12:39:43 ON 05 DEC 2007

=> file caplus

COST IN U.S. DOLLARS	ENTRY	SINCE FILE SESSION	TOTAL
FULL ESTIMATED COST		0.21	0.21

FILE 'CAPLUS' ENTERED AT 12:40:03 ON 05 DEC 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing

of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 5 Dec 2007 VOL 147 ISS 24
FILE LAST UPDATED: 4 Dec 2007 (20071204/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s MR16-1 or (PM-1 or MRA) and (IL-6 or (interleukin 6)
UNMATCHED LEFT PARENTHESIS 'AND (IL-6'
The number of right parentheses in a query must be equal to the
number of left parentheses.

=> s MR16-1 or (PM-1 or MRA) and (IL-6 or (interleukin 6))
22 MR16
9399859 1
15 MR16-1
(MR16(W)1)
43639 PM
3947 PMS
47190 PM
(PM OR PMS)
9399859 1
734 PM-1
(PM(W)1)
546 MRA
63 MRAS
600 MRA
(MRA OR MRAS)
132596 IL
1570 ILS
133636 IL
(IL OR ILS)
3998465 6
32229 IL-6
(IL(W)6)
168956 INTERLEUKIN
6421 INTERLEUKINS
171012 INTERLEUKIN
(INTERLEUKIN OR INTERLEUKINS)
3998465 6
40551 INTERLEUKIN 6
(INTERLEUKIN(W)6)

L1 76 MR16-1 OR (PM-1 OR MRA) AND (IL-6 OR (INTERLEUKIN 6))

=> duplicate remove

ENTER L# LIST OR (END):L1

PROCESSING COMPLETED FOR L1

L2 76 DUPLICATE REMOVE L1 (0 DUPLICATES REMOVED)

=> s L2 and mesothelioma

L3 76 S L2

2750 MESOTHELIOMA

580 MESOTHELIOMAS

2909 MESOTHELIOMA

(MESOTHELIOMA OR MESOTHELIOMAS)

L4 1 L3 AND MESOTHELIOMA

=> d L4 bib abs 1

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2006:887900 CAPLUS

DN 145:246150

TI Interleukin-6 induces both cell growth and VEGF
production in malignant mesotheliomas

AU Adachi, Yasuo; Aoki, Chieko; Yoshio-Hoshino, Naoko; Takayama, Koichi;
Curiel, David T.; Nishimoto, Norihiro

CS Laboratory of Immune Regulation, Graduate School of Frontier Biosciences,
Osaka University, Osaka, Japan

SO International Journal of Cancer (2006), 119(6), 1303-1311
CODEN: IJCNAW; ISSN: 0020-7136

PB Wiley-Liss, Inc.

DT Journal

LA English

AB Malignant mesothelioma (MM), an incurable tumor, is reportedly
an interleukin-6 (IL-6) secreting
tumor. The pathol. significance of IL-6
overexpression in this tumor, however, has remained unclear. We
investigated the biol. functions of IL-6 in
mesotheliomas. Five mesothelioma cell lines were
analyzed for IL-6 prodn. and IL-6
receptor (IL-6R) expression. Of them, 2 produced high levels of
IL-6, 2 produced intermediate levels and 1 cell line
showed no secretion. All mesothelioma cell lines used in this
study expressed very small amts. of IL-6R mRNA. We compensated for this
low level of IL-6R expression in mesotheliomas by adding
recombinant sol. IL-6R (sIL-6R) to mediate the IL-6
signal. IL-6 together with sIL-6R was found to
promote cell growth of H2052 and H226 MMs classified as high-level

IL-6 producers in a dose-dependent manner. Moreover, a humanized anti-IL-6R antibody (MRA) capable of blocking IL-6 signaling suppressed the cell growth of mesotheliomas induced by IL-6/sIL-6R. These findings demonstrate that IL-6 serves as an autocrine growth factor in the development of mesothelioma. In addn., IL-6/sIL-6R stimulation increased the expression of vascular endothelial growth factor (VEGF) in 4 out of 5 cell lines, and this induction was inhibited by MRA treatment. The involvement of the signal transducer and activator of transcription 3 (STAT3) pathway in both cell growth and VEGF induction by IL-6/sIL-6R was verified by dominant neg. STAT3 transduction combined with adenovirus gene-delivery methods. Although IL-6 induces VEGF through the JAK2/STAT3 pathway, anti-VEGF antibody could not inhibit the IL-6-induced cell growth obsd. in H2052 and H226. We concluded that IL-6-dependent growth does not occur via VEGF induction. These results suggest that treatment with anti-IL-6R antibody may constitute a potential mol. targeting therapy for MMs.

RE.CNT 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s L1 and mesothelium

2872 MESOTHELIUM

1 MESOTHELIUMS

19 MESOTHELIA

2882 MESOTHELIUM

(MESOTHELIUM OR MESOTHELIUMS OR MESOTHELIA)

L5 1 L1 AND MESOTHELIUM

=> d L5 bib abs 1

L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2006:887900 CAPLUS

DN 145:246150

TI Interleukin-6 induces both cell growth and VEGF production in malignant mesotheliomas

AU Adachi, Yasuo; Aoki, Chieko; Yoshio-Hoshino, Naoko; Takayama, Koichi; Curiel, David T.; Nishimoto, Norihiro

CS Laboratory of Immune Regulation, Graduate School of Frontier Biosciences, Osaka University, Osaka, Japan

SO International Journal of Cancer (2006), 119(6), 1303-1311

CODEN: IJCNAW; ISSN: 0020-7136

PB Wiley-Liss, Inc.

DT Journal

LA English

AB Malignant mesothelioma (MM), an incurable tumor, is reportedly an interleukin-6 (IL-6) secreting tumor. The pathol. significance of IL-6 overexpression in this tumor, however, has remained unclear. We investigated the biol. functions of IL-6 in mesotheliomas. Five mesothelioma cell lines were analyzed for IL-6 prodn. and IL-6 receptor (IL-6R) expression. Of them, 2 produced high levels of IL-6, 2 produced intermediate levels and 1 cell line showed no secretion. All mesothelioma cell lines used in this study expressed very small amts. of IL-6R mRNA. We compensated for this low level of IL-6R expression in mesotheliomas by adding recombinant sol. IL-6R (sIL-6R) to mediate the IL-6 signal. IL-6 together with sIL-6R was found to promote cell growth of H2052 and H226 MMs classified as high-level IL-6 producers in a dose-dependent manner. Moreover, a humanized anti-IL-6R antibody (MRA) capable of blocking IL-6 signaling suppressed the cell growth of mesotheliomas induced by IL-6/sIL-6R. These findings demonstrate that IL-6 serves as an autocrine growth factor in the development of mesothelioma. In addn., IL-6/sIL-6R stimulation increased the expression of vascular endothelial growth factor (VEGF) in 4 out of 5 cell lines, and this induction was inhibited by MRA treatment. The involvement of the signal transducer and activator of transcription 3 (STAT3) pathway in both cell growth and VEGF induction by IL-6/sIL-6R was verified by dominant neg. STAT3 transduction combined with adenovirus gene-delivery methods. Although IL-6 induces VEGF through the JAK2/STAT3 pathway, anti-VEGF antibody could not inhibit the IL-6-induced cell growth obsd. in H2052 and H226. We concluded that IL-6-dependent growth does not occur via VEGF induction. These results suggest that treatment with anti-IL-6R antibody may constitute a potential mol. targeting therapy for MMs.

RE.CNT 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

WEST Search History

DATE: Wednesday, December 05, 2007

<u>Hide?</u> <u>Set Name</u> <u>Query</u>	<u>Hit Count</u>
<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=ADJ</i>	
<input type="checkbox"/> L15 L11 and (antagonist or inhibitor)	8
<i>DB=EPAB; PLUR=YES; OP=ADJ</i>	
<input type="checkbox"/> L14 WO-2006041205-A1.did.	1
<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=ADJ</i>	
<input type="checkbox"/> L13 L12 and angiogenesis	6
<input type="checkbox"/> L12 L11 and (antagonist or inhibitor)	8
<input type="checkbox"/> L11 (apelin)[TI]	25
<input type="checkbox"/> L10 L9 and "apelin antibody"	3
<input type="checkbox"/> L9 L8 and antibody	15
<input type="checkbox"/> L8 L6 and angiogenesis and APJ	17
<input type="checkbox"/> L7 L6 and angiogenesis	58
<input type="checkbox"/> L6 ((apln or apel or (agtr1l ligand) or apelin) and (antagonist or inhibitor))	247
<input type="checkbox"/> L5 (apln or apel or (agtr1l ligand) or apelin) and (antagonist or inhibitor)	247
<input type="checkbox"/> L4 L3 and (anti-apelin)	3
<input type="checkbox"/> L3 L2 and (antagonist or inhibitor)	58
<input type="checkbox"/> L2 L1 and angiogenesis	65
<input type="checkbox"/> L1 (apln or apel or (agtr1l ligand) or apelin)	4038

END OF SEARCH HISTORY

A service of the U.S. National Library of Medicine [\[?\]](#)
and the National Institutes of Health
[\[Sign In\]](#) [\[Register\]](#)

All Databases PubMed Nucleotide Protein Genome Structure OMIM PMC
Journals Books

Search for

About Entrez

Text Version

[Limits](#) [Preview/Index](#) [History](#) [Clipboard](#) [Details](#)

Entrez PubMed

Overview

Help | FAQ

Tutorials

New/Noteworthy 

E-Utilities

- Search History will be lost after eight hours of inactivity.
- Search numbers may not be continuous; all searches are represented.
- To save search indefinitely, click query # and select Save in My NCBI.
- To combine searches use #search, e.g., #2 AND #3 or click query # for more options.

Search	Most Recent Queries	Time	Result
	#4 Search #2 and mesothelioma	12:34:37	0
	#2 Search MR16-1 or PM-1 and IL-6	12:31:20	16
	#1 Search MR16-1 or PM-1	12:31:08	343

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

Special Queries

LinkOut

My NCBI

Related Resources

Order Documents

NLM Mobile

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

A service of the U.S. National Library of Medicine
and the National Institutes of Health

[My NCBI](#) [?](#)

[Sign In](#) [Register](#)

All Databases
Journals

PubMed
Books

Nucleotide

Protein

Genome

Structure

OMIM

PMC

Search for

About Entrez

[Text Version](#)

[Entrez PubMed](#)

[Overview](#)

[Help | FAQ](#)

[Tutorials](#)

[New/Noteworthy](#) 

[E-Utilities](#)

[PubMed Services](#)

[Journals Database](#)

[MeSH Database](#)

[Single Citation Matcher](#)

[Batch Citation Matcher](#)

[Clinical Queries](#)

[Special Queries](#)

[LinkOut](#)

[My NCBI](#)

[Related Resources](#)

[Order Documents](#)

[NLM Mobile](#)

[NLM Catalog](#)

[NLM Gateway](#)

[TOXNET](#)

[Consumer Health](#)

[Clinical Alerts](#)

[ClinicalTrials.gov](#)

[PubMed Central](#)

Limits [Preview/Index](#) [History](#) [Clipboard](#) [Details](#)

Limits: Publication Date to 2005/1/14

- Search History will be lost after eight hours of inactivity.
- Search numbers may not be continuous; all searches are represented.
- To save search indefinitely, click query # and select Save in My NCBI.
- To combine searches use #search, e.g., #2 AND #3 or click query # for more options.

Search	Most Recent Queries	Time	Result
#16	Search #10 and angiogenesis Limits: Publication Date to 2005/1/14	13:46:03	0
#15	Search (apln or apel or (agtr1 ligand) or apelin) Limits: Publication Date to 2005/1/14	13:42:44	469
#14	Search (apln or apel or (agtr1 ligand) or apelin) and angiogenesis Limits: Publication Date to 2005/1/14	13:40:39	2
#13	Search (apln or apel or (agtr1 ligand) or apelin) and angiogenesis	13:31:26	8
#12	Search apln or apel or (agtr1 ligand) or apelin and angiogenesis	13:31:02	588
#10	Search apln or apel or (agtr1 ligand) or apelin and (antagonist or inhibitor)	13:30:00	34
#11	Search apln or apel or (agtr1 ligand) or apelin and (antagonist or inhibitor) and angiogenesis	13:29:46	0
#9	Search apln or apel or (agtr1 ligand) and (antagonist)	13:28:07	6
#8	Search apelin and (antagonist)	13:27:19	5
#7	Search apelin and (antagonist or agonist)	13:26:18	6
#3	Search apln or apel or (agtr1 ligand) and angiogenesis	13:19:53	3
#2	Search apln or apel or (agtr1 ligand)	13:15:42	583
#1	Search apln or apel	13:15:18	575

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)
[Department of Health & Human Services](#)
[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)